It could actually be cheaper than other treatment options.
Hemophilia B is a genetic condition affecting males more than females in which the patient's body does not produce sufficient protein levels called Factor IX . The protein is a clotting factor required to stop bleeding in the event of an injury or during surgery or other medical procedures.
. Treatment for such individuals constitutes intravenous infusions of clotting Factor IX to prevent bleeding episodes, which must be conducted over the patient's lifetime.Developed by Pennysylvania-based pharmaceutical company CSL Behring, Hemgenix is a one-timeproduct given through an intravenous infusion.
The intervention is expected to cost patients $3.5 million per dose, which might still be relatively cheaper than the $23 million hemophilia B patients shell out for infusions over their lifetime,Estimates suggest that there are around 8,000 patients of Hemophilia B in the U.S. This is rather a tiny number compared to the number of patients of other ailments, such as cardiovascular diseases or cancer, that pharmaceutical companies trial drugs for.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves $3.5 million treatment for hemophilia, now the most expensive drug in the world | CNNThe US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive drug in the world.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options. fba hemophilia kprc2 click2houston health us
Read more »
FDA approves $3.5 million gene therapy for hemophiliaThe Food and Drug Administration (FDA) approved a drug to treat adults with hemophilia B, a rare blood clotting disorder.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. Drugmaker CSL Behring announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options
Read more »